NuCana plc - American Depositary Share (NCNA): Price and Financial Metrics

NuCana plc - American Depositary Share (NCNA): $3.52

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add NCNA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#146 of 380

in industry

NCNA Price/Volume Stats

Current price $3.52 52-week high $23.75
Prev. close $3.52 52-week low $3.40
Day low $3.52 Volume 9,500
Day high $3.75 Avg. volume 52,981
50-day MA $5.05 Dividend yield N/A
200-day MA $9.90 Market Cap 9.30M

NCNA Stock Price Chart Interactive Chart >


NuCana plc - American Depositary Share (NCNA) Company Bio


NuCana plc develops anti-cancer medicines for ovarian, biliary, pancreatic, colorectal, haematology, oncology, and breast cancers. NuCana produces oncology medicines using a proprietary technology platform for cancer patients. The company was incorporated in 1997 and is based in Edinburgh, the United Kingdom.


NCNA Latest News Stream


Event/Time News Detail
Loading, please wait...

NCNA Latest Social Stream


Loading social stream, please wait...

View Full NCNA Social Stream

Latest NCNA News From Around the Web

Below are the latest news stories about NUCANA PLC that investors may wish to consider to help them evaluate NCNA as an investment opportunity.

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data Pipeline Continues to Advance with Data Updates Expected for all Programs in 2024 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Nov. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2023 and provided an update on its broad clinical development program with its transformative ProTi

Yahoo | November 16, 2023

NuCana Announces Listing Transfer to Nasdaq Capital Market

EDINBURGH, United Kingdom, Nov. 10, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced today that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Select Market to the Nasdaq Capital Market. This transfer became effective at the opening of business on November 9, 2023. The Nasdaq Capital Market is a continuous trading

Yahoo | November 10, 2023

NuCana to Present at the Jefferies London Healthcare Conference

EDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference. Event: Jefferies London Healthcare ConferenceDate: Tuesday, November 14, 2023Time: 8:00 AM GMTLocation: London, UK The presentation will be webcast live and available for replay under “Events & Presentations” in the Investo

Yahoo | November 8, 2023

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

EDINBURGH, United Kingdom, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Truist Securities 2023 BioPharma Symposium. Event: Truist Securities 2023 BioPharma SymposiumDate: November 8-9, 2023Location: New York, NY About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients wit

Yahoo | November 1, 2023

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed on Prior Immunotherapy, including Anti-PD-1 Therapy Several Patients Achieved Reductions in Tumor Volume and Prolonged Time on Treatment BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced a presentation on the ongoing NuTide:701 study of NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer T

Yahoo | October 16, 2023

Read More 'NCNA' Stories Here

NCNA Price Returns

1-mo -7.61%
3-mo -54.58%
6-mo -71.19%
1-year -83.44%
3-year -95.46%
5-year -99.07%
YTD -52.40%
2023 -55.18%
2022 -72.27%
2021 -46.99%
2020 -26.39%
2019 -57.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!